Find clinical trials

The aim of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 administrations of the Acne mRNA vaccine candidate at up to 3 dose levels (45 µg, 120 µg and 225 µg total mRNA) in adults aged 18 to 45 years with moderate to severe acne. This is a phase I/II trial, in which about 260 people will take part in this study worldwide. 36/260 will be randomized in Sentinel cohort A, 200 participants in the main cohort A and 24 participants in Sentinel cohort B.

This is a non-interventional observational study in participants with confirmed Type 1 VWD according to diagnostic guidelines. The study includes screening, a baseline evaluation, and an approximately 4-month observation period which will include every other week telemedicine check-ins (to monitor bleed diary entries and bleeding event treatments.?

This study aims to test the effectiveness of a new and improved version (version 2) of a virtual reality intervention designed to support the social and cognitive recovery of young people with early psychosis. The study will compare version 2 with the previous version 1, to determine if the new version is more effective in improving social functioning.

This is a Phase I clinical trial evaluating an investigational treatment called IDOVImmune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer

This Phase 2a, multicentre, placebo-controlled, single-blind, dose range-finding study will assess the safety, tolerability, pharmacodynamics, and preliminary efficacy of ascending doses of inhaled ALX1 or placebo administered for 14 days in adults with BE. The total duration of study participation for each participant will be up to 53 days, including Pre-screening and Screening of up to 32 (+ 2) days, a Treatment Period of 14 doses over up to 16 (± 1) days, and a Follow-up video or telephone call 1 (+ 1) day after the final dose.

The study is being done over 24 weeks to see whether an experimental drug called MTX-463 can slow or stop a lung disease called idiopathic pulmonary fibrosis (IPF) from worsening, in people >40 years of age who have IPF.

This study will follow-up the WITHDRAW-AF cohort, to evaluate long term outcomes of this cohort.

The main purpose of this study is to determine if XEN1101 can reduce seizure frequency in people with focal epilepsy and if it is safe to use. In this study 360 participants globally will be randomly assigned to receive either XEN1101 (25mg/day or 15mg/day) or placebo (an inactive substance) for 12 weeks, in addition to their usual anti-seizure medications.